Austria Drug Manufacturers - General news

10:30 12 Aug 2026

finance.yahoo.com Regulatory and legal Provider-linked mention 🇦🇹 Austria

Lilly calls on online platforms, payment companies and regulators to shut down the illegal retatrutide black market

Files six new lawsuits as company escalates fight to protect patients INDIANAPOLIS, Aug. 12, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today escalated its continued fight to protect patients from the dangerous black market for retatrutide, filing six new lawsuits against U.S. …

LLYC mentioned

Sharemaestro market context Trend signal active 52 weeks +73.7% · Next-week setup positive 56.3%

10:17 12 Aug 2026

nasdaq.com Market update Provider-linked mention 🇦🇹 Austria

If I Were in My 40s, I'd Buy This Vanguard ETF Warren Buffett Recommended and Hold It Forever

Key Points Warren Buffett steered the Berkshire Hathaway holding company to market-crushing returns for 60 years. He often said everyday investors could do well by simply buying an exchange-traded fund that tracks a diversified index like the S&P 500. In February 2014, he specifically …

LLYC mentioned

Sharemaestro market context Trend signal active 52 weeks +73.7% · Next-week setup positive 56.3%

09:25 12 Aug 2026

finance.yahoo.com Market update Main company 🇦🇹 Austria

AMGEN TO OPEN NEW SCIENCE & INNOVATION CENTER IN GENOME VALLEY, HYDERABAD

New Site Will Support Global Research and Development Capabilities and Advance Scientific Research HYDERABAD, India, Aug. 12, 2026 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced plans to open a new Science and Innovation Center at Genome Valley in Hyderabad. The center will join Amgen's …

AMGN main company

Sharemaestro market context Trend signal active 52 weeks +44.6%

08:10 12 Aug 2026

finance.yahoo.com Earnings Provider-linked mention 🇦🇹 Austria

Absci (ABSI) Is Up 11.0% After Lilly Backs ABS-201 With US$40 Million Investment – Has The Bull Case Changed?

Absci Corporation recently reported second-quarter 2026 results showing a net loss of US$33.21 million, wider than a year ago, while basic and diluted loss per share from continuing operations narrowed to US$0.21. Alongside these figures, Absci highlighted encouraging early Phase 1 data for ABS-201, …

LLYC mentioned

Sharemaestro market context Trend signal active 52 weeks +73.7% · Next-week setup positive 56.3%

06:41 12 Aug 2026

finance.yahoo.com Capital return Provider-linked mention 🇦🇹 Austria

Did Stronger Guidance, Buybacks and New Oncology Tests Just Shift Labcorp Holdings' (LH) Investment Narrative?

In late July and early August 2026, Labcorp reported higher second-quarter and year-to-date earnings, raised its 2026 revenue growth guidance, completed a large share repurchase program, and expanded its precision oncology offering by making Roche's FDA-approved VENTANA PTEN (SP218) RxDx Assay available nationwide to …

ROGH mentioned

Sharemaestro market context Price above Trend Line 42 weeks +35.0% · Next-week setup positive 57.1%

06:39 12 Aug 2026

finance.yahoo.com Earnings Provider-linked mention 🇦🇹 Austria

Pfizer (PFE) Agreed To A $44 Million Chantix Settlement

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Pfizer (NYSE:PFE) agreed to a US$44 million class action settlement related to its smoking cessation drug Chantix, addressing claims tied to product safety disclosures. …

PFE mentioned

Sharemaestro market context Price above Trend Line 52 weeks +13.3%

03:53 12 Aug 2026

finance.yahoo.com Earnings Provider-linked mention 🇦🇹 Austria

3 Healthcare Stocks with Open Questions

3 Healthcare Stocks with Open Questions Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from elevated demand, and their momentum is only rising as the industry has posted a 22.3% gain over …

GILD mentioned

Sharemaestro market context Price below Trend Line 52 weeks +17.3% · Next-week setup positive 55.8%

23:15 11 Aug 2026

finance.yahoo.com Earnings Main company 🇦🇹 Austria

AbbVie (ABBV) Wins Canada Reimbursement Backing For Adult Migraine Treatment

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. AbbVie (NYSE: ABBV) received a recommendation from Canada's Drug Agency to reimburse UBRELVY for the acute treatment of migraine in adults. The decision …

ABBV main company

Sharemaestro market context Trend signal active 52 weeks +23.7%

21:05 11 Aug 2026

finance.yahoo.com Market update Provider-linked mention 🇦🇹 Austria

MacroGenics Announces Achievement of $10 Million Milestone Following Gilead’s Exercise of Option to License Preclinical Bispecific Program

MacroGenics, Inc. ROCKVILLE, MD, Aug. 11, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that Gilead Sciences, Inc. has exercised its option to obtain an exclusive license …

GILD mentioned

Sharemaestro market context Price below Trend Line 52 weeks +17.3% · Next-week setup positive 55.8%

21:05 11 Aug 2026

finance.yahoo.com Earnings Provider-linked mention 🇦🇹 Austria

Absci Reports Business Updates and Second Quarter 2026 Financial and Operating Results

Absci Corporation Announced positive interim Phase 1 data from the HEADLINE™ trial of ABS-201 Completed $100 million underwritten offering, including $40 million strategic investment from Eli Lilly & Company Cash, cash equivalents, and marketable securities now sufficient to fund operations into the second half …

LLYC mentioned

Sharemaestro market context Trend signal active 52 weeks +73.7% · Next-week setup positive 56.3%

20:07 11 Aug 2026

finance.yahoo.com Regulatory and legal Main company 🇦🇹 Austria

Eli Lilly Scores Major Win in Weight-Loss Drug Race

This article first appeared on GuruFocus. Eli Lilly (NYSE:LLY) has secured U.K. approval for its once-daily weight-loss pill Foundayo, giving the drugmaker its first regulatory win for the treatment outside the U.S. and escalating its obesity battle with Novo Nordisk. The approval expands Lilly's …

LLYC main company NNO2 mentioned

Sharemaestro market context Trend signal active 52 weeks +73.7% · Next-week setup positive 56.3%

19:14 11 Aug 2026

finance.yahoo.com Regulatory and legal Main company 🇦🇹 Austria

Merck (MRK) Wins FDA And EMA Review For Broader RSV Use In Children

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Merck (NYSE:MRK) said the FDA and EMA have accepted supplemental applications to expand ENFLONSIA for preventing RSV in young children at elevated risk. …

MRK main company

Sharemaestro market context Trend signal active 52 weeks +59.8%

18:20 11 Aug 2026

finance.yahoo.com Earnings Provider-linked mention 🇦🇹 Austria

2 Stocks I Think Are Hands-Down Better Picks Than SpaceX Right Now

Space Exploration Technologies (NASDAQ: SPCX) has been perhaps the most talked-about stock on Wall Street since it completed the largest IPO ever in mid-June. Opinions on the company's prospects are divided. Some see an innovative company that has already disrupted the space travel industry …

LLYC mentioned

Sharemaestro market context Trend signal active 52 weeks +73.7% · Next-week setup positive 56.3%

17:54 11 Aug 2026

finance.yahoo.com Earnings Provider-linked mention 🇦🇹 Austria

How Much Did Immunology Drugs Contribute to AbbVie's Q2 Performance?

AbbVie ABBV announced encouraging second-quarter 2026 results last month, which beat expectations for both earnings and sales. A significant portion of this growth came from the continued strength of its two blockbuster immunology medications, Skyrizi and Rinvoq, which together accounted for more than 47% …

LLYC mentioned

Sharemaestro market context Trend signal active 52 weeks +73.7% · Next-week setup positive 56.3%

17:45 11 Aug 2026

finance.yahoo.com Earnings Provider-linked mention 🇦🇹 Austria

BridgeBio Q2 Earnings Miss, Revenues Beat as Attruby Sales Surge

BridgeBio Pharma BBIO reported a second-quarter 2026 loss of 78 cents per share, wider than the Zacks Consensus Estimate of a loss of 64 cents. Despite the miss, the figure improved compared to the year-ago loss of 95 cents. Revenues surged 120% year over …

PFE mentioned

Sharemaestro market context Price above Trend Line 52 weeks +13.3%

17:12 11 Aug 2026

finance.yahoo.com Analyst action Provider-linked mention 🇦🇹 Austria

Roche (SWX:ROG) Stock Fair Value Edges Higher As Analysts Weigh Pipeline Growth

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Roche Holding now sits on a refreshed fair value estimate of CHF 370.31, up from CHF 359.22. This gives you an updated reference point for where analysts …

ROGH mentioned

Sharemaestro market context Price above Trend Line 42 weeks +35.0% · Next-week setup positive 57.1%

17:00 11 Aug 2026

finance.yahoo.com Earnings Main company 🇦🇹 Austria

Pfizer (PFE) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Tuesday, Aug. 4, 2026 at 11:00 a.m. ET CALL PARTICIPANTS Chairman and Chief Executive Officer - Albert Bourla Chief Financial Officer - David Denton Incoming Interim Chief Financial Officer and Executive Vice President - Cecile Guegan Chief Scientific …

PFE main company

Sharemaestro market context Price above Trend Line 52 weeks +13.3%

16:12 11 Aug 2026

finance.yahoo.com Regulatory and legal Main company 🇦🇹 Austria

Lilly Takes Its Weight-Loss Pill Battle Overseas

This article first appeared on GuruFocus. Eli Lilly and Co. (LLY, Financials), the developer of Foundayo and Zepbound, has received U.K. approval for Foundayo, the first approval for the weight-loss medication outside of the U.S. The The strategy pits Lilly directly against Novo Nordisk's …

LLYC main company NNO2 mentioned

Sharemaestro market context Trend signal active 52 weeks +73.7% · Next-week setup positive 56.3%

15:30 11 Aug 2026

finance.yahoo.com Earnings Provider-linked mention 🇦🇹 Austria

REGN Soars 21.9% in a Month: Buy, Sell or Hold the Stock?

The going has been strong for Regeneron Pharmaceuticals REGN over the past month. Shares of this biotech giant have surged 21.9% over the said time frame, outpacing the industry's growth of 4%. The stock has also outperformed the sector and the S&P 500 Index …

ROGH mentioned

Sharemaestro market context Price above Trend Line 42 weeks +35.0% · Next-week setup positive 57.1%

14:48 11 Aug 2026

finance.yahoo.com Earnings Main company 🇦🇹 Austria

MRK Stock Up 5.6% in a Month as Estimates Fall: Buy, Hold or Sell?

Merck's MRK stock is up 5.6% in a month. The key reason for the increase was the strong second-quarter 2026 performance. Merck beat estimates for both earnings and sales in the second quarter. Revenues in the second quarter increased 5% to $16.61 billion as …

MRK main company

Sharemaestro market context Trend signal active 52 weeks +59.8%

14:40 11 Aug 2026

seekingalpha.com Market update Provider-linked mention 🇦🇹 Austria

These stocks have some of Wall Street’s lowest short interest

[short sale] abluecup Stocks including Apple, Alphabet, Exxon Mobil, and JPMorgan are among the companies with relatively low short interest, according to a screen of stocks with market capitalizations above $2B. The screen includes stocks with short interest between 1% and 2% of shares …

LLYC mentioned

Sharemaestro market context Trend signal active 52 weeks +73.7% · Next-week setup positive 56.3%

14:20 11 Aug 2026

finance.yahoo.com Deals and strategy Provider-linked mention 🇦🇹 Austria

A Profitable Rare-Disease Prize: Who Might Snap Up BioCryst?

Quick Read BioCryst hit its first full year of profitability in 2025, with Q2 2026 revenue up 34% to $218 million, fueling acquisition speculation. Takeda (TAK) tops the buyer rankings as navenibart directly threatens its Takhzyro franchise; AstraZeneca (AZN) ranks second through its Alexion …

SANO mentioned

Sharemaestro market context Trend signal started 52 weeks -4.9%

14:12 11 Aug 2026

finance.yahoo.com Earnings Provider-linked mention 🇦🇹 Austria

J&J Trading Above 200- & 50-Day SMAs: Buy, Sell or Hold the Stock?

Johnson & Johnson JNJ stock has been trading above both its 50-day and 200-day simple moving averages (SMAs) since mid-June. Trading above the 200-day SMA indicates that the stock's longer-term trend has turned positive, while staying above the 50-day SMA suggests that shorter-term momentum …

LLYC mentioned GILD mentioned

Sharemaestro market context Trend signal active 52 weeks +73.7% · Next-week setup positive 56.3%

14:00 11 Aug 2026

finance.yahoo.com Regulatory and legal Provider-linked mention 🇦🇹 Austria

The Galien Foundation Announces 2026 Prix Galien USA Nominees for "Best Biotechnology Product," "Best Pharmaceutical Product," and "Best Product for Rare/Orphan Diseases"

A Milestone 20th Anniversary Edition Recognizing Excellence in Medical Science and Patient Care NEW YORK, Aug. 11, 2026 /PRNewswire/ -- The Galien Foundation, the premier global institution dedicated to honoring innovators in life sciences, today announced the nominees for the 2026 Prix Galien USA …

MRK mentioned GILD mentioned PFE mentioned

Sharemaestro market context Trend signal active 52 weeks +59.8%

14:00 11 Aug 2026

finance.yahoo.com Market update Provider-linked mention 🇦🇹 Austria

Nucleai Advances AI-Powered Tissue Intelligence Through Large-Scale Oncology ADC Collaboration

Collaboration demonstrates how AI-powered Tissue Intelligence is transforming biomarker discovery, translational research, and precision oncology development. TEL AVIV, Israel, August 11, 2026--(BUSINESS WIRE)--Nucleai, a leader in AI-powered Tissue Intelligence, which integrates multimodal tissue image analysis with clinical data to deliver translational insights, today announced …

GILD mentioned

Sharemaestro market context Price below Trend Line 52 weeks +17.3% · Next-week setup positive 55.8%

13:44 11 Aug 2026

finance.yahoo.com Regulatory and legal Provider-linked mention 🇦🇹 Austria

Eli Lilly and Company (LLY) vs. Novo Nordisk A/S (NVO): Is Lilly Pulling Ahead in the $100 Billion Obesity Market?

The duopoly dominating the multi-billion-dollar GLP-1 weight-loss market has moved from pharmacy shelves to the federal courtroom. Novo Nordisk A/S (NYSE:NVO) filed a lawsuit in U.S. District Court in New Jersey against Eli Lilly and Company (NYSE:LLY) on July 21, accusing its primary rival …

LLYC mentioned NNO2 mentioned

Sharemaestro market context Trend signal active 52 weeks +73.7% · Next-week setup positive 56.3%

13:38 11 Aug 2026

finance.yahoo.com Earnings Provider-linked mention 🇦🇹 Austria

Cloud AI Today - Novo Nordisk Partners With AWS For AI-Driven Drug Discovery

Novo Nordisk has entered a strategic partnership with Amazon Web Services (AWS) to enhance drug discovery using artificial intelligence and cloud technologies. This collaboration includes establishing a co-innovation hub in London, which brings together AWS engineers, AI specialists, and Novo Nordisk's research and development …

NNO2 mentioned

Sharemaestro market context Trend signal active 52 weeks +27.1% · Next-week setup positive 55.2%

13:31 11 Aug 2026

finance.yahoo.com Earnings Provider-linked mention 🇦🇹 Austria

Pfizer Inc. (PFE) vs. BioNTech SE (BNTX): Which Pharma Giant Is Better Positioned for the Post-COVID Era?

Pfizer Inc. (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX), two companies forever linked by their historic COVID-19 vaccine partnership, reported Q2 2026 earnings alongside major strategic announcements. While the European Commission authorized their updated XFG-adapted COVID-19 vaccine on July 29, the two partners are traveling down …

PFE mentioned

Sharemaestro market context Price above Trend Line 52 weeks +13.3%

13:30 11 Aug 2026

finance.yahoo.com Market update Provider-linked mention 🇦🇹 Austria

ILiAD Biotechnologies Expands Board of Directors and Appoints Chief Business Officer

Suha Jhaveri, Bill Warren and Jim Wassil added to ILiAD Board of Directors; Antony Blanc appointed Chief Business Officer Appointments deepen vaccine development expertise and enhance global commercial and strategic leadership WESTON, Fla., August 11, 2026--(BUSINESS WIRE)--ILiAD Biotechnologies, Inc. (ILiAD), an advanced clinical stage …

MRK mentioned

Sharemaestro market context Trend signal active 52 weeks +59.8%

12:43 11 Aug 2026

nasdaq.com Analyst action Main company 🇦🇹 Austria

NVO Crosses Above Average Analyst Target

In recent trading, shares of Novo-Nordisk AS (Symbol: NVO) have crossed above the average analyst 12-month target price of $47.48, changing hands for $47.73/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on …

NNO2 main company

Sharemaestro market context Trend signal active 52 weeks +27.1% · Next-week setup positive 55.2%

12:05 11 Aug 2026

finance.yahoo.com Deals and strategy Main company 🇦🇹 Austria

AbbVie Piles on $8 Billion in Debt for Its Apogee Deal -- Should Dividend Investors Worry?

AbbVie (NYSE: ABBV) is aiming high with its $10.6 billion planned purchase of Apogee Therapeutics (NASDAQ: APGE). The deal, pending regulatory approvals, is expected to close in the third quarter. The move is designed to supplement the pharmaceutical giant's already strong immunology portfolio. However, …

ABBV main company

Sharemaestro market context Trend signal active 52 weeks +23.7%

12:03 11 Aug 2026

finance.yahoo.com Market update Main company 🇦🇹 Austria

Veeva Vault CRM Selected by Eli Lilly and Company

PLEASANTON, Calif., Aug. 11, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Eli Lilly and Company (Lilly) has committed to Veeva Vault CRM globally.Veeva Vault CRM Selected by Eli Lilly and Company Vault CRM is part of the Vault CRM Suite of …

LLYC main company

Sharemaestro market context Trend signal active 52 weeks +73.7% · Next-week setup positive 56.3%

09:45 11 Aug 2026

finance.yahoo.com Guidance Provider-linked mention 🇦🇹 Austria

Non-Viral Transfection Reagents Market Report (3rd Edition) by Type of Non-Viral Transfection Method, Application Area, End-User & Region, Featuring Bio-Rad, MaxCyte, MilliporeSigma, Thermo Fisher Scientific

Company Logo Dublin, Aug. 11, 2026 (GLOBE NEWSWIRE) -- The "Non-Viral Transfection Reagents Market (3rd Edition) by Type of Non-Viral Transfection Method, Application Area, End-User and Geographical Regions-Trends and Forecast Till 2035" has been added to ResearchAndMarkets.com's offering. The global non-viral transfection reagents market …

GILD mentioned

Sharemaestro market context Price below Trend Line 52 weeks +17.3% · Next-week setup positive 55.8%

08:30 11 Aug 2026

nasdaq.com Regulatory and legal Main company 🇦🇹 Austria

Eli Lilly's Foundayo Wins UK Approval

(RTTNews) - Eli Lilly and Company's (LLY) oral GLP-1 pill Foundayo has secured UK regulatory approval for weight management and type 2 diabetes, making the UK the first European country to clear the once-daily tablet. The decision by the Medicines and Healthcare products Regulatory …

LLYC main company

Sharemaestro market context Trend signal active 52 weeks +73.7% · Next-week setup positive 56.3%

00:29 11 Aug 2026

finance.yahoo.com Earnings Main company 🇦🇹 Austria

Why the Amlitelimab Setback Isn’t Enough to Sink Sanofi’s Multi-Billion Dollar Engine

It was reported on July 24 that Sanofi (NASDAQ:SNY) shares underperformed in European trading following the company's decision to drop the clinical development of its eczema candidate, amlitelimab, for moderate-to-severe atopic dermatitis. Rather than a fundamental breakdown, the move reflects an aggressive R&D pipeline …

SANO main company

Sharemaestro market context Trend signal started 52 weeks -4.9%

00:20 11 Aug 2026

finance.yahoo.com Analyst action Main company 🇦🇹 Austria

Eli Lilly (LLY) Stock Gets Fair Value Bump After GLP 1 Driven Analyst Revisions

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Eli Lilly's updated fair value price target has shifted from US$1,270.37 to US$1,297.31, giving investors a fresh reference point for how analysts are framing the …

LLYC main company

Sharemaestro market context Trend signal active 52 weeks +73.7% · Next-week setup positive 56.3%